Bolt Biotherapeutics, Inc. (BOLT) Stock Forecast
BOLT analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.00 / 5 from 4 analysts
- Price target
- $29.00 average of analyst targets
- Upside to target
- +625.0% from the latest close
- Next earnings
- November 11, 2026 EPS estimate $-2.40
- 52-week range
- $3.18 – $7.09
BOLT analyst ratings
4 analystsNumber of analysts at each rating.
BOLT price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
BOLT earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$3.69 | −$4.65 | −$2.72 | −$3.72 | +0.9% | 2 |
| Current fiscal year (2026) | −$26.29 | −$34.30 | −$18.27 | −$17.06 | −54.1% | 2 |
| Next fiscal year (2027) | −$20.19 | −$24.74 | −$15.64 | −$26.29 | +23.2% | 2 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
BOLT revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $368,330 | $0 | $900,000 | −83.0% | 3 |
| Current fiscal year (2026) | $200,000 | $0 | $400,000 | −97.4% | 2 |
| Next fiscal year (2027) | $3.5M | $0 | $7.0M | +1,650.0% | 2 |
BOLT EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
BOLT revenue: reported and forecast
BOLT EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$29.44 | −$20.43 | −$20.43 | −$20.43 | −$3.69 | −87.5% | 0 up · 0 down |
| Current fiscal year (2026) | −$351.88 | −$238.28 | −$238.28 | −$238.28 | −$26.29 | −92.5% | 0 up · 0 down |
| Next fiscal year (2027) | −$254.96 | −$254.96 | −$254.96 | −$254.96 | −$20.19 | −92.1% | 0 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
BOLT earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; BOLT beat in 7 of 12.
What analysts expect from BOLT
4 analysts cover Bolt Biotherapeutics; their consensus rating is buy (4.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $29.00, 625.0% above the latest close of $4.00. Analysts expect earnings of −$26.29 per share for 2026, −54.1% from a year earlier. For 2027 the average estimate is −$20.19 per share on revenue of $3.5 million. Bolt Biotherapeutics beat the EPS estimate in 7 of the last 12 quarters.
Related: BOLT income statement, BOLT key metrics, BOLT chart. See the BOLT stock overview for the latest quote and news.
BOLT forecast FAQ
What is Bolt Biotherapeutics's price target?
The average analyst price target for Bolt Biotherapeutics is $29.00, 625.0% above the latest close of $4.00.
Is Bolt Biotherapeutics a buy, hold or sell?
Of 4 analysts covering Bolt Biotherapeutics, 2 rate it a strong buy, 0 a buy, 2 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Bolt Biotherapeutics's EPS forecast?
Analysts forecast −$26.29 per share for 2026 (range −$34.30 to −$18.27); for 2027 the estimate is −$20.19.
What is Bolt Biotherapeutics's revenue forecast?
The average revenue estimate for 2026 is $0.2 million, growth of −97.4%; for 2027 it is $3.5 million.
When does Bolt Biotherapeutics report earnings?
Bolt Biotherapeutics is expected to report results for the quarter ending September 30, 2026 on November 11, 2026; the EPS estimate is $-2.40.
Does Bolt Biotherapeutics usually beat earnings estimates?
Bolt Biotherapeutics reported EPS at or above the analyst estimate in 7 of the last 12 quarters.